AFT Pharmaceuticals Ltd Ordinary Shares
AFT.NZXHealth Care
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.
Market Data
$3.930
0.0%$412.1M
28.0x
$0.141
0.46%
+0.4%
Latest Earnings
AFT delivers double digit revenue growth and record earning
21 May 2026
AFT Pharmaceuticals delivered a record FY26 result with revenue rising 22% to NZD $254.7 million, driven by double-digit growth across all territories including Australia (+19%), New Zealand (+11%), Asia (+41%), and International (+66%). Operating profit reached a record $24.4 million, ahead of the guidance range of $20-24 million and up 39% on FY25, while NPAT grew 24% to $14.1 million. The company issued strong FY27 guidance targeting operating profit of $28-32 million and revenue exceeding $300 million, and raised its dividend to 2.5 cents per share. Key points: Record operating profit of $24.4 million, up 39% on FY25 and ahead of guidance range of $20-24 million; Revenue grew 22% to $254.7 million with double-digit growth across all four territories: Australia (+19%), New Zealand (+11%), Asia (+41%), International (+66%); Licensing income nearly quadrupled to $3.1 million (FY25: $0.7 million), reflecting growing out-licensing momentum including a China deal for novel IV iron therapy with Grand Life Sciences Group
Recent Announcements
Annual Meeting and Closing Date for Director Nominations
AFT Pharmaceuticals Limited announces its Annual Meeting of Shareholders will be held on 31 July 2026 in Auckland, New Zealand, with a director nominations closing date of 11 June 2026 at 5:00pm NZT.
issue of unlisted Options
AFT Pharmaceuticals Limited issued 495,000 unlisted options under its Long Term Incentive Plan with an exercise price of $3.49, representing approximately 0.46% of ordinary shares on issue. The options vest in three tranches subject to EBITDA performance hurdles and employee retention, with a two-year exercise period following vesting.
FY26 dividend distribution notice
AFT Pharmaceuticals Limited is distributing a fully imputed final dividend of NZD $0.025 per share (gross $0.034722) on 3 July 2026, with a total distribution value of NZD $2.62 million sourced from retained earnings.
AFT delivers double digit revenue growth and record earning
AFT Pharmaceuticals delivered a record FY26 result with revenue rising 22% to NZD $254.7 million, driven by double-digit growth across all territories including Australia (+19%), New Zealand (+11%), Asia (+41%), and International (+66%). Operating profit reached a record $24.4 million, ahead of the guidance range of $20-24 million and up 39% on FY25, while NPAT grew 24% to $14.1 million. The company issued strong FY27 guidance targeting operating profit of $28-32 million and revenue exceeding $300 million, and raised its dividend to 2.5 cents per share. Key points: Record operating profit of $24.4 million, up 39% on FY25 and ahead of guidance range of $20-24 million; Revenue grew 22% to $254.7 million with double-digit growth across all four territories: Australia (+19%), New Zealand (+11%), Asia (+41%), International (+66%); Licensing income nearly quadrupled to $3.1 million (FY25: $0.7 million), reflecting growing out-licensing momentum including a China deal for novel IV iron therapy with Grand Life Sciences Group
AFT Pharmaceuticals names Stuart Houliston CFO
AFT Pharmaceuticals announced that Stuart Houliston will commence as Chief Financial Officer on 15 June 2026, replacing Malcolm Tubby who retires on 29 May 2026. Houliston joins from Sanford and brings financial expertise from public markets and accounting (previously an audit director at KPMG).
AFT to announce full year results on May 21 2026v
AFT Pharmaceuticals will release its full year FY2026 results (ended March 31 2026) on May 21 2026 at 09:00 am NZT, followed by a management webinar presentation at 10:30 am NZT.
March Quarter FY 2026 Investor Update
AFT Pharmaceuticals reported record FY26 sales with sustained double-digit growth across all markets and confirmed operating earnings guidance of $20-24 million, while announcing a new US distribution partnership with Cost Plus (backed by Mark Cuban) for Maxigesic Rapid tablets, successful integration of South Africa's Pharma Dynamics acquisition, and advancement of its novel injectable iron treatment following positive FDA meetings.
Chief Financial Officer update
AFT Pharmaceuticals announced that CFO-designate Simon Bosley has withdrawn from the role for personal reasons, creating a leadership gap in the finance function. The outgoing CFO Malcolm Tubby remains set to retire at end of May 2026, while Bosley has agreed to stay until end of July 2026 to support the transition during recruitment. This is a personnel/governance announcement with no financial results or trading update disclosed. Key points: Simon Bosley has committed to remain with AFT until end of July 2026, providing continuity during the CFO search; The company is actively recruiting a permanent CFO replacement, limiting the duration of leadership uncertainty; Outgoing CFO Malcolm Tubby remains in place until end of May 2026, ensuring experienced oversight in the near term
Court of Appeal dismisses PBL Port Wine Stain profit claim
AFT Pharmaceuticals has won a Court of Appeal judgment dismissing PBL Solutions Limited's claim for a share of profits from AFT's use of Pascomer for Port Wine Stain (PWS) treatment, a potentially large non-orphan market with circa 36 times more patients than the orphan indication. AFT retains full rights to any profits from non-orphan applications of Pascomer, while continuing to share 35% of orphan drug profits with PBL. The company confirms the judgment has no material effect on its FY2026 earnings guidance. Key points: Court of Appeal dismissed PBL's appeal, confirming AFT retains full rights to profits from Pascomer used in non-orphan indications such as Port Wine Stains; PWS represents a significantly larger commercial opportunity than the orphan Facial Angiofibroma indication, with approximately 36 times more potential patients; FY2026 earnings guidance is confirmed as unaffected by the judgment
AFT to announce half year interim results Nov 20
AFT Pharmaceuticals announced it will release its half-year interim results for the period ended September 30, 2025 on November 20, 2025 at 09:00, followed by a management presentation via teleconference at 10:30.
Get real-time alerts for AFT
Receive AI-powered earnings summaries and instant notifications when AFT Pharmaceuticals Ltd Ordinary Shares releases results.
Register Free